See more : Hingtex Holdings Limited (1968.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Avalon GloboCare Corp. (AVCO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avalon GloboCare Corp., a leading company in the Real Estate – Services industry within the Real Estate sector.
- Shanghai Tongji Science&Technology Industrial Co.,Ltd (600846.SS) Income Statement Analysis – Financial Results
- HORNBACH Holding AG & Co. KGaA (HBBHF) Income Statement Analysis – Financial Results
- Aurubis AG (AIAGY) Income Statement Analysis – Financial Results
- Alabama Power Company (ALPVN) Income Statement Analysis – Financial Results
- Nishikawa Rubber Co., Ltd. (5161.T) Income Statement Analysis – Financial Results
Avalon GloboCare Corp. (AVCO)
About Avalon GloboCare Corp.
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.26M | 1.20M | 1.39M | 1.38M | 1.55M | 1.56M | 1.08M | 616.45K | 0.00 |
| Cost of Revenue | 1.02M | 929.44K | 976.45K | 987.56K | 1.21M | 1.17M | 829.79K | 73.07K | 0.00 |
| Gross Profit | 238.19K | 272.73K | 414.52K | 390.20K | 339.91K | 388.01K | 247.76K | 543.38K | 0.00 |
| Gross Profit Ratio | 18.97% | 22.69% | 29.80% | 28.32% | 21.98% | 24.84% | 22.99% | 88.15% | 0.00% |
| Research & Development | 109.62K | 731.33K | 1.03M | 883.86K | 1.78M | 39.06K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.64M | 5.66M | 8.22M | 11.96M | 16.93M | 7.68M | 2.79M | 459.55K | 31.01K |
| Selling & Marketing | 1.67M | 1.33M | 328.57K | 294.35K | 685.06K | 335.90K | 15.25K | 6.89K | 0.00 |
| SG&A | 7.31M | 6.98M | 8.22M | 11.96M | 16.93M | 8.02M | 2.80M | 466.45K | 31.01K |
| Other Expenses | 8.57M | -120.51K | 4.27K | -4.98K | 3.26K | -11.35K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.99M | 7.72M | 9.25M | 12.84M | 18.71M | 7.96M | 2.78M | 466.45K | 31.01K |
| Cost & Expenses | 17.01M | 8.65M | 10.22M | 13.83M | 19.91M | 9.13M | 3.61M | 539.51K | 31.01K |
| Interest Income | 0.00 | 3.58M | 200.48K | 168.76K | 82.91K | 4.31K | 1.37K | 575.00 | 0.00 |
| Interest Expense | 1.35M | 3.58M | 200.48K | 168.76K | 82.91K | 314.65K | 138.11K | 0.00 | 0.00 |
| Depreciation & Amortization | 329.95K | 466.28K | 438.78K | 378.48K | 506.74K | 522.84K | 181.64K | 26.00 | 175.51K |
| EBITDA | -15.03M | -7.89M | -8.39M | -12.08M | -16.90M | -7.16M | -3.73M | 77.53K | -31.01K |
| EBITDA Ratio | -1,196.61% | -593.84% | -607.58% | -880.57% | -1,192.42% | -454.97% | -218.21% | 12.48% | 0.00% |
| Operating Income | -15.75M | -7.44M | -8.83M | -12.45M | -18.37M | -7.63M | -3.88M | 76.93K | -31.01K |
| Operating Income Ratio | -1,254.59% | -619.12% | -635.08% | -903.93% | -1,187.81% | -488.46% | -359.88% | 12.48% | 0.00% |
| Total Other Income/Expenses | -953.33K | -3.14M | -256.67K | -225.42K | 1.31M | -421.16K | -171.78K | 575.00 | 0.00 |
| Income Before Tax | -16.71M | -11.93M | -9.09M | -12.68M | -18.07M | -8.05M | -4.05M | 77.51K | -31.01K |
| Income Before Tax Ratio | -1,330.51% | -992.44% | -653.54% | -920.29% | -1,168.60% | -515.42% | -375.82% | 12.57% | 0.00% |
| Income Tax Expense | 0.00 | 749.25K | 144.29K | 112.11K | 30.39K | -278.17K | -585.36K | 21.93K | -175.50K |
| Net Income | -16.71M | -12.68M | -9.23M | -12.79M | -18.10M | -7.77M | -3.46M | 55.58K | -31.01K |
| Net Income Ratio | -1,330.51% | -1,054.77% | -663.91% | -928.43% | -1,170.57% | -497.61% | -321.50% | 9.02% | 0.00% |
| EPS | -1.59 | -1.36 | -1.09 | -1.61 | -2.41 | -1.08 | -0.53 | 0.01 | -0.18 |
| EPS Diluted | -1.59 | -1.36 | -1.09 | -1.61 | -2.41 | -1.08 | -0.53 | 0.01 | -0.18 |
| Weighted Avg Shares Out | 10.53M | 9.33M | 8.49M | 7.95M | 7.51M | 7.20M | 6.50M | 5.11M | 175.00K |
| Weighted Avg Shares Out (Dil) | 10.53M | 9.33M | 8.49M | 7.95M | 7.51M | 7.20M | 6.50M | 5.11M | 175.00K |
Avalon GloboCare inks definitive agreement to acquire Chinese cell therapy company Senlang Biotechnology
Avalon GloboCare Announces Execution of Purchase Agreement for Acquisition of SenlangBio in All Stock Transaction
Avalon GloboCare to Present at the Noble Capital Markets Investor Forum During the 16th Annual World Stem Cell Summit on June 17, 2021
Avalon GloboCare says CEO to present S-layer nanotechnology, QTY code platforms at 2021 World Stem Cell Summit
Avalon GloboCare is seeking to tap the power of cells to fight cancer and coronavirus
Avalon GloboCare to partner with University of Pittsburgh Medical Center Hillman Cancer Center to develop therapies using FLASH-CAR tech
Avalon GloboCare Announces Collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center to Advance Clinical Development of Cellular Immunotherapies Using the FLASH-CAR™ Platform
Avalon GloboCare expands its MIT co-development research program to fight cancer spread
Avalon GloboCare seeking to tap the power of cells to fight cancer and coronavirus
Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Expand Partnership and Accelerate Development of S-Layer Based Vaccines and Cellular Therapeutics
Source: https://incomestatements.info
Category: Stock Reports